Free Trial

AstraZeneca (AZN) Stock Forecast & Price Target

£122.38
-178.00 (-1.43%)
(As of 05:53 AM ET)

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

£121.57
High Forecast£150
Average Forecast£121.57
Low ForecastGBX 9,900
TypeCurrent Forecast
6/20/23 to 6/19/24
1 Month Ago
5/21/23 to 5/20/24
3 Months Ago
3/22/23 to 3/21/24
1 Year Ago
6/20/22 to 6/20/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
Consensus Price Target£121.57£117.57£117.13£119.25
Get AstraZeneca Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaMedical Companies
Consensus Rating Score
2.56
2.70
Consensus RatingModerate BuyModerate Buy
News Sentiment RatingNeutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/18/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold£110-11.50%
6/7/2024Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy£130 ➝ £150+19.13%
6/4/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight
5/28/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
5/21/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold£113-8.55%
5/21/2024Shore Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
4/8/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight£125+18.56%
2/12/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
2/12/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSell£107 ➝ GBX 9,900+4.16%
9/25/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target£127 ➝ £129+15.72%
4/11/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target£127 ➝ £119+2.20%
2/10/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Dominic Lunn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target£118+3.60%
2/9/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Keyur Parekh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetGBX 6,950-37.65%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:17 AM ET.

AZN Forecast - Frequently Asked Questions

What is AstraZeneca's stock forecast and purchase recommendation?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is £121.57, with a high forecast of £150 and a low forecast of GBX 9,900. The consensus rating for AstraZeneca stock is Moderate Buy based on the current 1 sell rating, 2 hold ratings and 6 buy ratings for AZN. Learn more on AZN's analyst rating history.

Do Wall Street analysts like AstraZeneca more than its competitors?

Analysts like AstraZeneca less than other "medical" companies. The consensus rating score for AstraZeneca is 2.56 while the average consensus rating score for "medical" companies is 2.70. Learn more on how AZN compares to other companies.

Is AstraZeneca being upgraded by Wall Street analysts?

Over the previous 90 days, AstraZeneca's stock had 1 upgrade by analysts.

Does AstraZeneca's stock price have much upside?

According to analysts, AstraZeneca's stock has a predicted upside of 7.11% based on their 12-month stock forecasts.

What analysts cover AstraZeneca?

AstraZeneca has been rated by research analysts at Barclays, Berenberg Bank, Citigroup, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, JPMorgan Chase & Co., and Shore Capital in the past 90 days.


Stock Forecasts and Research Tools

This page (LON:AZN) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners